NET-DNA, CCDC25, and ILC3 Repair in Ulcerative Colitis

Ulcerative colitis (UC) is commonly viewed through the lens of persistent inflammation, but durable recovery also depends on rebuilding the intestinal epithelial barrier. The 2026 FASEB Journal research article DNA From Neutrophil Extracellular Traps Restricts Group 3 Innate Lymphoid Cells Function in Intestinal Epithelial Repair via CCDC25 addresses an important gap in this area: how neutrophil extracellular traps (NETs) interfere with epithelial repair after mucosal injury.

The authors propose a pathway in which NET-derived DNA suppresses IL-22 production by group 3 innate lymphoid cells (ILC3s) through the DNA sensor CCDC25 and downstream ILK–HIF-1α signaling. The resulting reduction in IL-22 is associated with weaker mucus production, lower tight-junction protein expression, and impaired epithelial barrier recovery.

Study Background and Research Question

IL-22 is a key tissue-protective cytokine in the intestine. It promotes epithelial cell growth, supports mucus production, regulates permeability, and enhances expression of tight-junction proteins such as ZO-1 and occludin. ILC3s are an important intestinal source of IL-22, so changes in ILC3 activity can directly affect mucosal regeneration.

Previous observations showed that the proportion of ILC3s and IL-22-positive ILC3s falls in dextran sulfate sodium-induced colitis. At the same time, activated neutrophils release NETs: extracellular DNA frameworks decorated with histones and other granular proteins. NET accumulation and circulating cell-free DNA are increased in inflammatory disease, but whether NET-DNA directly compromises repair-related lymphocyte function remained unclear.

The central research question was therefore whether NET-DNA suppresses ILC3-derived IL-22 and, if so, which receptor and intracellular pathway mediate this effect. The study also asked whether removing NET-DNA could improve epithelial repair in vivo.

Key Innovation from the Reference Study

The main innovation is the identification of a specific immune-to-epithelial repair axis rather than a general association between NETs and tissue damage. The proposed sequence is:

1. Neutrophils generate excessive NETs during experimental colitis.
2. NET-DNA accumulates in the intestinal environment and contributes to disease severity.
3. ILC3s detect NET-DNA through coiled-coil domain containing protein 25 (CCDC25).
4. CCDC25-associated ILK–HIF-1α signaling reduces IL-22 secretion.
5. Lower IL-22 weakens epithelial proliferation, mucus production, and tight-junction maintenance.

This framing is significant because it distinguishes NET-DNA from other DNA sources. According to the reference study, NET-DNA had a pronounced inhibitory effect on IL-22, whereas other tested forms of DNA had comparatively little influence. The work therefore assigns NET-derived nucleic acid an active immunoregulatory role in epithelial healing.

Methods and Experimental Design Insights

The experimental design connected animal pathology with molecular and functional assays. Wild-type mice and PAD4-deficient mice were used to examine the contribution of NET formation. PAD4 is involved in the chromatin decondensation process required for NET release, so the knockout model provided a genetic approach for reducing NET-associated DNA. DNase I treatment supplied a complementary intervention by degrading extracellular DNA.

The investigators assessed circulating cell-free DNA and intestinal NET-DNA, while disease activity and tissue repair were evaluated through mucosal and cellular measurements. RNA sequencing compared transcriptional profiles between wild-type and PAD4-deficient animals and highlighted IL-22-related changes. Flow cytometry then localized the functional effect to ILC3s, with particular attention to the IL-22-positive ILC3 fraction.

Mechanistic experiments used isolated ILC3s and the mouse lymphocyte cell line MNK3. These cells were co-incubated with NET-DNA to test whether the material could directly suppress IL-22 production. CCDC25 expression was examined in ILC3s, and short-hairpin RNA-mediated CCDC25 knockdown was used in MNK3 cells to test receptor dependence. The authors further examined ILK and HIF-1α as downstream components by pharmacologically inhibiting this signaling branch.

Finally, the study established a two-cell in vitro repair model. Supernatants from NET-DNA-treated MNK3 cells were transferred to Caco-2 epithelial cells. Barrier performance was evaluated with FITC-dextran permeability, while ZO-1 expression provided a structural readout of tight-junction integrity. This arrangement was useful because it tested whether an altered lymphocyte secretome could transmit the NET-DNA effect to epithelial cells.

Protocol Parameters

• Experimental colitis: The reference study used a dextran sulfate sodium-induced UC mouse model and compared wild-type with PAD4−/− animals; exact induction conditions should be taken from the full article when reproducing the model.
• Extracellular DNA intervention: DNase I was used in vivo to eliminate extracellular DNA, while isolated NET-DNA was used for gain-of-function stimulation in cellular assays.
• Immune-cell analysis: Colon lamina propria lymphocytes were analyzed by flow cytometry to quantify ILC3s and IL-22-positive ILC3s.
• Receptor testing: CCDC25 dependence was evaluated with shCCDC25-MNK3 cells rather than inferred only from expression measurements.
• Barrier assessment: Conditioned medium from MNK3 cultures was applied to Caco-2 cells, followed by FITC-dextran permeability and ZO-1 measurements.

Core Findings and Why They Matter

UC mice displayed elevated circulating cell-free DNA, with the study identifying NET by-products as a major contributor. Intestinal NET-DNA worsened colitis-associated outcomes, whereas DNase I treatment alleviated disease features. The parallel improvement observed in PAD4−/− mice strengthens the interpretation that NET formation, rather than cell-free DNA in the abstract, is biologically relevant.

RNA sequencing identified substantial IL-22-related differences between wild-type and PAD4-deficient mice. Flow-cytometry data further showed that NET-DNA primarily affected IL-22 secretion by ILC3s. In both DNase I-treated and PAD4-deficient animals, the IL-22-positive ILC3 proportion was restored. This recovery coincided with increased mucin, tight-junction proteins, and Ki67, a marker associated with epithelial proliferation.

The cellular experiments provided direct mechanistic support. NET-DNA reduced IL-22 in primary ILC3s and MNK3 cells, but this inhibition was lost after CCDC25 knockdown. Inhibiting downstream ILK–HIF-1α signaling increased IL-22 production, placing this pathway between CCDC25 engagement and cytokine suppression.

The epithelial co-culture results extended the mechanism to barrier function. Supernatant from NET-DNA-treated MNK3 cells increased FITC-dextran permeability and reduced ZO-1 expression in Caco-2 cells. Thus, the study links an extracellular DNA signal to a measurable epithelial defect through altered ILC3 behavior. Conceptually, this shifts NET-DNA from a passive marker of inflammation to a candidate driver of delayed mucosal repair.

Comparison with Existing Internal Articles

The internal article Cy5 TSA Fluorescence System Kit: Reliable Signal Amplification focuses on scenario-based use of fluorescence enhancement in immunohistochemistry, in situ hybridization, and immunocytochemistry. Its practical emphasis differs from the reference study, which establishes a NET-DNA–CCDC25–IL-22 mechanism in experimental colitis rather than evaluating an imaging reagent.

A second related resource, Cy5 TSA Fluorescence System Kit: Signal Amplification for..., discusses horseradish peroxidase catalyzed tyramide deposition and sensitive visualization of scarce targets. That workflow could be relevant when researchers need to localize CCDC25, IL-22, NET markers, or epithelial junction proteins in tissue sections, but the reference paper does not report using a TSA system. Accordingly, these resources should be viewed as methodological complements, not as evidence validating the biological conclusions.

Limitations and Transferability

Several limitations affect how broadly the findings can be interpreted. First, the evidence is based largely on experimental mouse colitis, engineered PAD4 deficiency, cultured MNK3 cells, and Caco-2 epithelial monolayers. These models isolate key variables but do not reproduce the cellular diversity, treatment history, microbiota, or chronic relapse patterns of human UC.

Second, NET-DNA is released together with proteins and other inflammatory components in vivo. Although the study used isolated NET-DNA and DNA-degrading treatment to strengthen causality, complete separation of DNA effects from associated NET material remains technically difficult. DNase I can also alter the extracellular inflammatory environment beyond the precise signal sensed by ILC3s.

Third, MNK3 cells are a useful mechanistic model but are not equivalent to all intestinal ILC3 subsets. The relative contribution of different ILC3 populations, their tissue localization, and their responses during human disease require further study. Likewise, Caco-2 permeability and ZO-1 measurements provide a controlled barrier assay but do not capture stromal, vascular, neuronal, or microbiome-dependent repair signals.

Why this cross-domain matters, maturity, and limitations

The study creates a reasonable bridge between mechanistic immunology and spatial tissue analysis. Fluorescent labeling for in situ hybridization or protein imaging could help determine where NET-DNA, CCDC25-positive ILC3s, IL-22, and epithelial junction markers are located relative to one another. However, imaging can establish spatial association, not by itself prove that CCDC25 signaling causes IL-22 suppression. Such applications should therefore be treated as validation and localization strategies that complement genetic, biochemical, and functional experiments.

Research Support Resources

The reference study suggests that future work should validate the CCDC25–ILK–HIF-1α pathway in human UC samples and determine whether restoration of ILC3-derived IL-22 consistently improves epithelial barrier properties. For tissue-based validation, researchers can use the Cy5 Tyramide Signal Amplification (TSA) Fluorescence System Kit (SKU K1052) to support high-sensitivity fluorescence workflows in immunohistochemistry, immunocytochemistry, or in situ hybridization. Its horseradish peroxidase catalyzed tyramide deposition format may be useful when imaging detection of low-abundance targets is limited by conventional labeling, provided that appropriate controls and independent functional assays are included.